Abstract Library

#4635 Comparison of 18F-DOPA PET/CT and 68Ga-DOTATOC PET/CT and their impact on response to PRRT in midgut neuroendocrine tumours

Introduction: 18F-DOPA PET/CT is a powerful diagnostic test for assessing tumour burden in midgut neuroendocrine tumours (NETs). 68Ga-DOTATOC PET/CT is required for patient selection for PRRT.

Conference:

Presenting Author: Longo M

Authors: Longo M, Coccarelli A, Henry T, Kamoun T, Morbelli S,

Keywords: F-DOPA, Ga-DOTATOC, PRRT, midgut,

#4523 Preoperative evaluation of tumour border using radiomics and its surgical guidance in pancreatic neuroendocrine tumours

Introduction: Pancreatic neuroendocrine tumours are a heterogeneous group of tumours originating from peptidergic neurons and neuroendocrine cells with variable survival outcomes. Surgical resection is the mainstay of treatment. However, there is an ambiguous insight into the real need to execute the standard surgery in small pancreatic neuroendocrine tumours. The tumour border is a powerful determinant of survival prognosis in many tumours and is often used as a safety guarantee for parenchyma-sparing resections. However, there are no studies evaluating tumour border with or without preoperative imaging in pNETs.

Conference:

Presenting Author: Wang Y

Authors: Wang Y, Gu W, Tang W, Huang D, Zhang W,

Keywords: pancreatic neuroendocrine tumour, border, computed tomography, enucleation, radiomics,

#4255 Prognostic significance of nodal micrometastases in patients with non-functioning pancreatic neuroendocrine tumors (NF-PanNETs) – A survival analysis from a prospective observational study

Introduction: Nodal metastases (N+) are one of the most powerful predictors of disease recurrence after surgery for non-functioning pancreatic neuroendocrine tumors (NF-PanNETs). However, the prognostic role of nodal metastases

Conference:

Presenting Author: Andreasi V

Authors: Andreasi V, Partelli S, Schiavo Lena M, Muffatti F, Battistella A,

Keywords: nodal metastases, micrometastases, surgery, prognosis, recurrence, pancreatic neuroendocrine,

#4231 Analysis of AI-based clinical trial search tool usage reveals motivations of neuroendocrine tumors patients in searching for trials

Introduction: It is challenging to recruit neuroendocrine tumors (NETs) patients to clinical trials. Delays in trial recruitment are detrimental to progress in clinical research. One potential reason for delays is that many patients report not being offered trials.

Conference:

Presenting Author: Mailman J

Authors: Ralic D, Mailman J,

Keywords: AI, patient engagement, clinical research, NET, clinical trials,

#4156 Status of the ongoing SORENTO clinical trial: Assessing efficacy and safety of high-exposure octreotide subcutaneous depot in patients with GEP-NET

Introduction: Somatostatin receptor ligands (SRLs) are first-line standard of care therapies for gastroenteropancreatic neuroendocrine tumors (GEP-NET). Retrospective data suggest higher-dose SRLs may benefit patients with GEP-NET.

Conference:

Presenting Author: Singh S

Authors: Singh S, Capdevila J, Ang Chan J, de Herder W, Grozinsky-Glasberg S,

Keywords: CAM2029, GEP-NET, high plasma exposure, octreotide, randomised active-controlled, somatostatin receptor ligands, SORENTO,